Brimonidine (Mirvaso) , dermal use
Van Genechten, D.
Journal de Pharmacie de Belgique 2: 45-46
2015
ISSN/ISBN: 0047-2166 PMID: 26466509 Document Number: 682072
Document emailed within 1 workday
Related Documents
Pessach, Y.; Goldberg, I.; Sprecher, E.; Gat, A.; Harel, A. 2014: An unusual presentation of congenital dermal melanocytosis fitting the rare diagnosis of dermal melanocyte hamartoma Cutis 94(4): E16-E17Hashiguchi, A.; Kano, T.; Nakamura, M.; Shibata, Y.; Sasaoka, Y.; Matsuyama, K.; Morioka, T.; Mishima, M.; Yasutake, S.; Nakano, M. 1990: Dermal patch anesthesia to prevent pain from dermal puncture--10% lidocaine aqueous gel with 3% glycyrrhetinic acid 3-0 hemiphthalate disodium Masui. Japanese Journal of Anesthesiology 39(4): 473-477
Pinsuwan, S.; Amnuaikit, T.; Ungphaiboon, S.; Itharat, A. 2010: Liposome-containing Hibiscus sabdariffa calyx extract formulations with increased antioxidant activity, improved dermal penetration and reduced dermal toxicity Journal of the Medical Association of Thailand 93(Suppl 7): S216-S226
Hoyng, P.F.; Rasker, M.T. 1998: Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost Nederlands Tijdschrift Voor Geneeskunde 142(39): 2138-2141
Tanghetti, E.A.; Jackson, J.M.; Belasco, K.T.; Friedrichs, A.; Hougier, F.; Johnson, S.M.; Kerdel, F.A.; Palceski, D.; Hong, H.C.-H.; Hinek, A.; Cadena, M.J.R. 2015: Optimizing the use of topical brimonidine in rosacea management: panel recommendations Journal of Drugs in Dermatology: Jdd 14(1): 33-40
Hondeghem, K.; Augustinus, B.; De Smet, M.D. 2009: Bilateral granulomatous uveitis as a side effect of topical brimonidine: two case reports Bulletin de la Societe Belge d'Ophtalmologie 2009(311): 51-52
Zabriskie, N.; Netland, P.A. 2003: Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials Advances in Therapy 20(2): 92-100
Gold, L.S.; Papp, K.; Lynde, C.; Lain, E.; Gooderham, M.; Johnson, S.; Kerrouche, N. 2017: Treatment of Rosacea with Concomitant use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: a Randomized, Vehicle-controlled Study Journal of Drugs in Dermatology: Jdd 16(9): 909-916
Hofmann, M.A.; Kokolakis, G. 2017: A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea Journal of Cosmetic and Laser Therapy 19(4): 222-224
Ruangvaravate, N.; Kitnarong, N.; Metheetrairut, A.; Danwiriyakul, W. 2002: Efficacy of brimonidine 0.2 per cent as adjunctive therapy to beta-blockers: a comparative study between POAG and CACG in Asian eyes Journal of the Medical Association of Thailand 85(8): 894-900
Urban, J.; Siripunvarapon, A.H.; Meekings, A.; Kalowitz, A.; Markowitz, O. 2014: Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment Journal of Drugs in Dermatology: Jdd 13(7): 821-826
Moore, A.; Kempers, S.; Murakawa, G.; Weiss, J.; Tauscher, A.; Swinyer, L.; Liu, H.; Leoni, M. 2014: Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study Journal of Drugs in Dermatology: Jdd 13(1): 56-61
Mondal, D.; Hasnain, M.G.; Hossain, M.S.; Ghosh, D.; Ghosh, P.; Hossain, H.; Baker, J.; Nath, R.; Haque, R.; Matlashewski, G.; Hamano, S. 2016: Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol Bmj Open 6(5): E010050
Fowler, J.; Jackson, M.; Moore, A.; Jarratt, M.; Jones, T.; Meadows, K.; Steinhoff, M.; Rudisill, D.; Leoni, M. 2013: Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies Journal of Drugs in Dermatology: Jdd 12(6): 650-656
McClinton, M.A. 1996: The use of dermal-fat grafts Hand Clinics 12(2): 357-364
Bourlond, A.; Decroix, J.; Dobbelaere, F.; Lissoir, A. 1974: Dermal alternariosis Annales de Dermatologie et de Syphiligraphie 101(4): 413-415
Kreysel, H.W.; Kimmig, J. 1974: Dermal changes in rheumatic diseases Der Internist 15(6): 304-311
Van Hale, H.M.; Turkel, S.B.; Rea, T.H. 1984: Dermal ultrastructure in leprosy Archives of Pathology and Laboratory Medicine 108(5): 383-386
Tsukada, S.; Ikeda, M.; Kumagai, T. 1971: Evaluation of dermal overgrafting Shujutsu. Operation 25(2): 159-163
Alegre, A.; Gómez, J.M.; Velasco, A.; Vicente, V. 1987: Dermal necrosis and heparin Medicina Clinica 88(4): 170